Viking Therapeutics
(NASDAQ) VKTX
Viking Therapeutics Financials at a Glance
Market Cap
$4.89BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$472.34M
EPS (TTM)
-$4.15
P/E Ratio
-10.16
Dividend
$0.00
Beta (Volatility)
1.26 (Average)
Dividend
$0.00
Beta (Volatility)
1.26 (Average)
Price
$42.19
Volume
4,359,821
Open
$39.09
Price
$42.19
Volume
4,359,821
Open
$39.09
Previous Close
$42.13
Daily Range
$38.68 - $42.79
52-Week Range
$22.96 - $43.15
Estimated Earnings Date
Jul 29, 2026
Dividend
$0.00
Beta (Volatility)
1.26 (Average)
Price
$42.19
Volume
4,359,821
Open
$39.09
Previous Close
$42.13
Daily Range
$38.68 - $42.79
52-Week Range
$22.96 - $43.15
Estimated Earnings Date
Jul 29, 2026
VKTX News
VKTX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Viking Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
59
CEO
Brian Lian, PhD, MBA
Website
www.vikingtherapeutics.comHeadquarters
San Diego, CA 92121, US
VKTX Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-71.31%
Return on Capital
-61.54%
Return on Assets
-77.66%
Earnings Yield
-9.84%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$4.89BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
116.11M
Volume
4.36M
Avg. Volume
2.41M
Financials (TTM)
Gross Profit
-$208.00K
Operating Income
-$502.00M
EBITDA
-$471.98M
Operating Cash Flow
-$340.33M
Capital Expenditure
$0.00
Free Cash Flow
-$340.33M
Cash & ST Invst.
$602.96M
Total Debt
$0.00
Viking Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
$4.89BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$82.91M
N/A
Employees
59
N/A
Net Income
-$158.33M
-247.0%
EBITDA
-$158.33M
-248.0%
Quarterly Fundamentals
Total Cash
$602.96M
-29.2%
Total Debt
$0.00
-100.0%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$0.00
-100.0%
Return on Assets
-77.66%
N/A
Return on Invested Capital
-1.00%
N/A
Free Cash Flow
-$113.98M
-117.8%
Operating Cash Flow
-$113.98M
-117.8%